BDT272

BDT272 is a first-in-class small molecule drug developed by Biodol Therapeutics for the treatment of chronic neuropathic pain. It functions as a negative allosteric modulator (NAM) of the FMS-like tyrosine kinase 3 (FLT3) receptor tyrosine kinase, which has been identified as a critical factor in the initiation and maintenance of chronic pain states. In preclinical models, BDT272 demonstrated superior safety and efficacy compared to established treatments such as pregabalin and duloxetine. Additionally, BDT272 has shown the potential to potentiate opioid-induced analgesia while simultaneously preventing the development of opioid tolerance and hyperalgesia, offering a potential strategy to mitigate the opioid crisis. The compound entered Phase 1 clinical trials in healthy volunteers in late 2024, with primary results anticipated in early 2026.

Other names

BDT272BDT-272BDT 272